Bird, Paul http://orcid.org/0000-0002-2277-8337
Littlejohn, Geoffrey http://orcid.org/0000-0002-7896-055X
Butcher, Belinda http://orcid.org/0000-0002-1415-4065
Smith, Tegan http://orcid.org/0000-0002-2944-9712
O’Sullivan, Catherine http://orcid.org/0000-0003-0564-9768
Witcombe, David
Griffiths, Hedley http://orcid.org/0000-0001-5869-797X
Article History
Received: 19 May 2021
Revised: 24 June 2021
Accepted: 29 June 2021
First Online: 9 August 2021
Declarations
:
: This research protocol was approved by the University of New South Wales HREC (HC17221).
: The activities of OPAL Rheumatology Ltd have received overarching ethics approval from the UNSW Human Research Ethics Committee (HREC), based on a patient opt-out arrangement (HC17799). This research protocol was approved by the UNSW HREC (HC17221).
: Patients have consented to publication of data on an opt-out basis. All data is de-identified.
: PB has received consulting/speaker bureaus for Abbvie, Jannsen, BMS, Pfizer, Novartis, Gilead, Eli-Lilly, and imaging consulting for Synarc, BICL. GL has no conflicts of interest to report. BB is an independent statistical consultant, funded by OPAL. HG has attended advisory board meetings for AbbVie and Lilly and has received speaker bureaus for Lilly. TS has no conflicts to report. COS has no conflicts of interest to report. DW is an employee of Pfizer.